Who makes Tegaserod and Polyethylene Glycol 3350?

Tegaserod and Polyethylene Glycol 3350 is developed by Novartis.

What development phase is Tegaserod and Polyethylene Glycol 3350 in?

Tegaserod and Polyethylene Glycol 3350 is FDA-approved (marketed).

Last reviewed 2026-05-13 · How we verify

Tegaserod and Polyethylene Glycol 3350

Novartis · FDA-approved active Small molecule Quality 0/100

Tegaserod and Polyethylene Glycol 3350, marketed by Novartis, holds a position in the pharmaceutical market with a key composition patent expiring in 2028. The drug's key strength lies in its unique mechanism of action, which differentiates it from competitors. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic name	Tegaserod and Polyethylene Glycol 3350
Sponsor	Novartis
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Preference of Tegaserod vs. PEG 3350 in Patients With Constipation (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Tegaserod and Polyethylene Glycol 3350 CI brief — competitive landscape report
Tegaserod and Polyethylene Glycol 3350 updates RSS · CI watch RSS
Novartis portfolio CI